Axatilimab
Axatilimab is a monoclonal antibody that targets the colony-stimulating factor 1 receptor (CSF-1R). It is being investigated for its potential use in treating various inflammatory and fibrotic diseases, including chronic graft-versus-host disease (cGVHD).
Mechanism of Action[edit | edit source]
Axatilimab is designed to bind to the CSF-1R, a receptor found on the surface of certain immune cells, including macrophages. By inhibiting this receptor, axatilimab can modulate the activity of macrophages, which play a crucial role in inflammation and fibrosis. This mechanism is particularly relevant in conditions like cGVHD, where macrophages contribute to the pathological process.
Clinical Development[edit | edit source]
Axatilimab is currently undergoing clinical trials to evaluate its safety and efficacy. Early-phase studies have shown promising results in reducing symptoms and improving outcomes in patients with cGVHD. The drug is being developed by Syndax Pharmaceuticals in collaboration with other research institutions.
Potential Indications[edit | edit source]
While the primary focus of axatilimab's development is for cGVHD, its mechanism of action suggests potential applications in other diseases characterized by macrophage-driven inflammation and fibrosis. These may include certain types of pulmonary fibrosis, systemic sclerosis, and other autoimmune conditions.
Safety and Side Effects[edit | edit source]
As with any monoclonal antibody therapy, axatilimab may have side effects. Commonly reported adverse effects in clinical trials include infusion-related reactions, fatigue, and gastrointestinal symptoms. Ongoing studies aim to further characterize the safety profile of axatilimab.
Regulatory Status[edit | edit source]
As of the latest update, axatilimab has not yet received approval from major regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It remains an investigational drug under clinical evaluation.
Also see[edit | edit source]
- Monoclonal antibody therapy
- Chronic graft-versus-host disease
- Macrophage
- Fibrosis
- Syndax Pharmaceuticals
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
